Archives

Ardian takes majority stake in CNC technology company imes-icore

Ardian logo

Ardian takes majority stake in CNC technology company imes-icore

Eiterfeld/Frankfurt, August 2nd 2017 – Ardian, the independent private investment company, today announces the acquisition of a majority stake in imes-icore GmbH (imes-icore), a specialist manufacturer of computer numerical control (CNC) and computer aided design/manufacturing (CAD/CAM) systems predominantly focusing on the medical industry, and headquartered in Eiterfeld, Germany.

Ardian will acquire the stake from current majority shareholder, Hugo Isert, as part of a succession planning programme. Current CEO, Christoph Stark, will retain a significant minority stake, and will continue to manage the business. In the course of this transaction, members of the management team will also become shareholders in the company.

imes-icore_logo

imes-icore was founded in 2002 by Hugo Isert and Christoph Stark, and develops, produces and sells specialist CNC-CAD/CAM systems for milling, water jet and laser cutting, and 3D printing. The company has close to 150 employees and in 2016 generated sales of approximately EUR 30 million.

imes-icore’s main competency lies in machine systems for the automated production of dentures such as dental caps and bridges, implant superstructures or prostheses. The company’s products are used in dental laboratories, clinics and dental milling centres. imes-icore also offers specialized industrial production solutions for numerous industries such as e.g. jewellery, orthopaedic and automotive sectors as well as for model/mould construction. Sales to customers in more than 100 countries are handled primarily through distribution partners.

With the support of Ardian, imes-icore plans to increase its range of services and key account management as well as expanding internationally, both organically and through targeted acquisitions.

Christoph Stark, CEO and co-founder of imes-icore, said: “The partnership with Ardian is an important milestone in the development of imes-icore. Ardian’s extensive industrial experience, financial strength and global platform will support us in realising our potential for national and international growth. Our well-established brand, unique product and service portfolio, and clear focus on innovation is valued by customers worldwide. We intend to grow our strong market position in our core segment by further building on our dental laboratories business as well as expanding our activities in the segments of practice laboratories and automated systems for milling centres. We will continue to develop these specific market segments going forward, on both the product development and sales sides.”

Marc Abadir, Managing Director of Ardian Expansion, said: “imes-icore is acknowledged throughout the industry as a leading provider of innovative technology solutions for the dental sector. It has significant potential for growth in a fragmented market environment, led by a highly capable CEO, Christoph Stark. We look forward to supporting the company and management team in realising the firm’s potential for growth.”

This is the fifth investment of Ardian Expansion Fund IV which closed at €1 billion in 2016. The fund invests in high-growth companies with a value of up to EUR 225 million in France, Italy, Belgium, Germany, Austria, Switzerland and Spain.

The transaction remains subject to approval from the competition authorities, and financial details have not been disclosed.

ABOUT ARDIAN

Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$62 billion managed or advised in Europe, North America and Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty and entrepreneurship.

Ardian maintains a truly global network, with more than 460 employees working through twelve offices in Beijing, Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, New York, Paris, San Francisco, Singapore and Zurich. The company offers its 580 investors a diversified choice of funds covering the full range of asset classes, including Ardian Funds of Funds (primary, early secondary and secondary), Ardian Private Debt, Ardian North America Direct Buyout, Direct Funds (Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth, Ardian Co-Investment), Ardian Infrastructure, Ardian Real Estate and customized mandate solutions with Ardian Mandates.

www.ardian.com

ABOUT IMES-ICORE

Imes-icore was established in 2002 as a spin-off from the isel Group, which has been in business since 1972. The company currently has around 150 employees at its Eiterfeld site. It develops, produces and sells specialist CNC-CAD/CAM systems for milling, water jet and laser cutting as well as 3D-printing. The firm’s products are used in dental laboratories, clinics and dental milling centres. imes-icore also offers specialized industrial production solutions for numerous industries such as e.g. jewellery, orthopaedic and automotive sectors as well as for model/mould construction. Sales to customers in more than 100 countries are handled primarily through distribution partners. imes-icore generated sales of around EUR 30 million in 2016.

www.imes-icore.de

COMPANIES AND INDIVIDUALS INVOLVED IN THE TRANSACTION

Ardian Team: Marc Abadir, Dirk Wittneben, Yannic Metzger, Max Dolata
Financial: Deloitte (Egon Sachsalber)
Commercial: L.E.K. (Tobias Kösters, Nicole Damani)
Legal Corporate: Orrick, Herrington & Sutcliffe (Dr. Christoph Brenner, Dr. Fabian von Samson)
Legal Finance: Willkie, Farr & Gallagher (Jan Wilms)
Tax: Taxess (Gerald Thomas, Richard Schäfer)
Insurance: Aon (Dr. Christoph von Lehmann)
M&A Advisory: Raymond James (Dirk-Oliver Löffler)
Debt Advisory: DC Advisory (Daniel Gebler)
M&A Advisory (sell-side): UniCredit (Michael Bälz, Garbor Grailach)
Legal (sell-side): McDermott, Will & Emery (Dr. Clemens Just, Norman Wasse)

Categories: News

Tags:

Investment in Middle eastern bakery business

Mizuho logo

Investment in the Middle Eastern bakery business via the Gulf Japan Food Fund, a Private Equity fund set up to promote exports to that region -Supporting expansion of Japanese food and agricultural exports-

 

In July 2017, the Gulf Japan Food Fund (below: “GJFF”), owned by investors including Mizuho Bank, Ltd. (President & CEO: Koji Fujiwara) and The Norinchukin Bank (President & CEO：Yoshio Kono), invested in Yamanote Atelier Restaurant LLC (below: “Yamanote”; owners: Sheikh Suhail Al Maktoum, Mrs Hamda Al Thani), a firm developing a Japanese bakery business in Dubai, U.A.E.

The GJFF is a private equity fund set up to promote export growth of Japan’s agricultural, forestry and fisheries products and the food security of the six Gulf Cooperation Council countries (below: “GCC”), mainly in financial terms. The fund began investment operations on 3 March, 2016. Fund stakeholders on the Japanese side, apart from Mizuho Bank and Norinchukin Bank, also include the Cool Japan Fund, a public/private fund. Those on the Middle Eastern side include the Gulf Investment Corporation (GIC), and sovereign wealth funds. Together, all these organizations have collectively invested USD 390 million.

Yamanote is a bakery chain established by Dubai’s Ruling Family, based on the concept of “Japanese Bakery”. It emphasizes high quality and food safety, and imports most of the ingredients from Japan. The firm plans to benefit from this time’s investment round by constructing central kitchen facilities and expanding its branch network mainly in the GCC countries.

By supporting Yamanote’s business expansion through investment, the GJFF intends to promote further export growth not only of Japan’s agricultural products like dairy goods, wheat, rice and azuki beans but also the country’s other food and agricultural products like confectionery goods and beverages.

Going forward, Mizuho Bank and Norinchukin Bank plan to continue contributing to the creation of added value and new markets in the agricultural and food business, via the GJFF.

Mizuho Bank, Ltd.

The Norinchukin Bank

 

 

Categories: News

Tags:

EQT Mid Market invests in a group which owns ILA Vietnam

eqt-logo

EQT Mid Market invests in a group which owns ILA Vietnam

  • EQT Mid Market invests in a group which owns ILA Vietnam, a premium market leader in the English Language Training (“ELT”) sector in Vietnam
  • Strategy is to support continued growth and development of the company to stay ahead of its peers, through enhancements of the academic product offering, learning experience and environment, and network expansion, by leveraging on EQT’s experience and network globally

The EQT Mid Market investment strategy (“EQT Mid Market”) invests in a group which owns ILA Vietnam (“ILA” or the “Company”). An early pioneer in the premium ELT industry, ILA has a well-established reputation and a history that goes more than 20 years back. Today, ILA has over 20,000 ELT enrollments across Vietnam, and in addition offers overseas study consultancy, teacher training services and corporate English training.  ILA strives to be at the forefront in delivering high quality and up-to-date programs to its students across Vietnam.

Mr. Johan Bygge, Chairman of EQT Asia Pacific said: “We are excited to see EQT Mid Market join forces with a market leader in Vietnam’s ELT sector such as ILA. The vast EQT experience, insights and network in the education sector globally, will be of great support in taking ILA to the next level.”

“We are impressed by the Company’s premium curriculum offering and delivery methods, which have been key reasons for its long-term success. Going forward, there will be very interesting opportunities to grow the ILA offering to students all across Vietnam.” says Mr. Tak Wai Chung, Partner at EQT Partners, Investment Advisor to EQT Mid Market.

Contacts
Tak Wai Chung, Partner at EQT Partners, Investment Advisor to EQT Mid Market +65 6595 1830
EQT Press Office +46 8 506 55 334

About EQT
EQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.
More info: www.eqtpartners.com

About ILA Vietnam
ILA Vietnam is a leading premium ELT service provider in Vietnam. The Company offers premium English Language Training, overseas study consultancy, teacher training services and corporate English training.
More info: http://ilavietnam.edu.vn/

Categories: News

Tags:

Electra Director declaration

Director Declaration

31 July 2017

Electra Private Equity PLC announces that John McAdam, a non-executive director of the Company, has been appointed as a Non-executive Director and Senior Independent Director of Cobham plc, effective from 3 August 2017. He will also become a member of the Remuneration and Nomination Committees of Cobham plc.

Electra Private Equity PLC

Categories: People

Schroders completes acquisition of Adveq

Schroder Adveq

Schroders is today announcing the completion of the acquisition of Adveq, a leading asset manager investing in private equity globally.

The acquisition, which was announced on 20 April 2017, has now received approval from the regulators. Adveq has been renamed Schroder Adveq.

The acquisition of Adveq accelerates the growth of Schroders private assets business, with more than $7 billion of client commitments, complementing existing capabilities and expertise in the real estate and infrastructure finance sectors.

Sven Lidén, CEO of Schroder Adveq commented:

“We are pleased to have received such a high level of support from our clients and other stakeholders for our partnership with Schroders.

Schroder Adveq, as we are now known, remains committed to delivering the strong investment performance and high quality client service that investors have come to expect from our team over the 20 years since we first launched.”

Stephen Mills has joined the Schroder Adveq board as Executive Chairman. Bruno Raschle, founder of Schroder Adveq, remains on the board in a new capacity of non-executive Vice Chairman.

Headquartered in Switzerland, Schroder Adveq employs over 100 people around the world. Adveq’s clients include some of the largest and most highly regarded institutional investors and pension funds in Switzerland and Germany. In recent years, Adveq has also successfully established a premium client base in the US and other international markets.

For further information on Schroder Adveq, please contact:

Anelia Fikiina, CNC Communications

Tel: +44 (0)203 219 8887 /  schroderadveq@cnc-communications.com

Categories: News

Tags:

Marle completes the acquisition of SMB Medical

ik-investment-partners

Marle, the leading European orthopaedic manufacturer backed by IK VII Fund since 2016, is accelerating its development through the acquisition of SMB Medical. Marle acquired 100 percent of the shares of SMB Holding AG, the parent company of SMB Medical SA, from Swiss Patrimonium Private Equity and various minority shareholders. The transaction was closed on 27 July 2016.

Based in Sant’Antonino, Switzerland, and with 85 employees, SMB Medical is a well-established contract manufacturer, producing tailor-made forged orthopaedic implants in all available medical alloys.

Unifying the complementary companies SMB Medical and Marle secures long-term prospects of both brands. Customers will benefit from an extended product range and broader geographic presence. The enlarged group consolidates its rank amongst the top three contract manufacturers for orthopaedic implants worldwide and as the European leader offering one-stop-shop solutions for their customers across the globe.

Heimo Wabusseg, CEO of SMB Medical, is enthusiastic about the acquisition: “by integrating with Marle, SMB Medical will further grow its position in the market by expanding its customer portfolio and investing in new technologies.”

“With SMB Medical, we gain access to attractive new customer segments. SMB Medical offers high quality standards and will enrich the group with a complementary and adjacent product range,” added Antonio Gil, CEO of Marle.

“The acquisition of SMB Medical is a key milestone in the development of Marle, adding additional manufacturing capabilities and a deep understanding of the market,” said Rémi Buttiaux, Partner at IK Investment Partners.

The financial terms of the transaction are not disclosed.

For any questions, please contact:

IK Investment Partners
Mikaela Hedborg
Director Communications & ESG
Phone: +44 77 87 573 566

About Marle
Marle has a 30-year track record serving the orthopaedic implant industry and specialises in the precision forging, machining and finishing of hip knee, shoulder, spine and extremities implants as well as instruments. It has acquired and developed a wide span of technologies dedicated to the medical industry and now offers one of the most comprehensive ranges of manufacturing services in the orthopaedics market. From a modest forging operation with 11 employees in 1978, Marle was shaped into the European leader it is today. For more information, visit www.marle.fr

About SMB Medical
SMB Medical has a history of almost 30 years in the production of orthopaedic and osteosynthesis implants in all available medical grade titanium alloys, cobalt chrome alloys and stainless steels. It uses state-of-the-art technology of forging, machining and finishing processes to develop custom solutions for its clients in the orthopaedic market. For more information, visit www.smb-medical.com

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €9 billion of capital and invested in over 100 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

Categories: News

Tags:

Hydrawell appoints CEO

Hydrawell appoints CEO

28 July 2017 – Rapidly growing plug & abandonment (P&A) and well repair specialists HydraWell has appointed Mark Sørheim as its new chief executive officer.

Mark Sørheim joins HydraWell from Schlumberger in Aberdeen where he held the position as integrated drilling & completion project director. Sørheim has spent almost 20 years in Schlumberger, including management roles in UK, Norway and France as well as operational roles in UK, Colombia and India.

“I have cooperated with HydraWell while at Schlumberger and have been highly impressed. When someone tells you that they can plug a well in 2-3 days instead of the 10-14 days it takes with conventional methods, most people will probably be a bit cautious at first. However, HydraWell’s perf, wash & cement technology does just that. It is by far the oil and gas market’s most cost-efficient P&A solution and I cannot wait to start working with the technology full time,” says Mark Sørheim, newly appointed CEO of HydraWell.

Mark Sørheim succeeds HydraWell’s co-founder Odd Engelsgjerd, who will continue to support the company as business advisor, board member and major shareholder.

“This transition has been planned for some time, by the board of directors and I, as part of our strategy to grow the business further,” says Odd Engelsgjerd.

HydraWell has developed the proprietary PWC®-technology (perforate, wash and cement) that plugs offshore wells in 2-3 days, compared to the traditional method of section milling which takes considerably longer time to complete. So far more than 200+ Hydrasystem plugs have been installed worldwide on behalf of 16 operators including supermajors, majors, NOCs and independent oil companies.

HydraWell is jointly owned by the company’s management and private equity fund Norvestor VII, L.P., which is advised by Norvestor Equity AS – a leading private equity firm focusing on lower mid-market control investments in the Nordic region.

Categories: People

Tags:

EQT VII to acquire leading specialist mortgage provider BlueStep Bank

  • EQT VII to acquire Sweden based BlueStep Bank, the leading specialist mortgage provider in the Nordic region
  • BlueStep Bank has pioneered the specialist mortgage market in Sweden and Norway, providing more than 29,000 customers with loans since 2005
  • EQT VII will support BlueStep Bank on its continued growth and transformation journey by investing in the organization and supporting further expansion

The EQT VII fund (“EQT VII”) and Bregal Investments (“Bregal”) announced today that EQT VII has entered into an agreement to acquire BlueStep Holding AB (“BlueStep Bank” or “the Company”) from funds managed by Bregal Capital LLP and advised by EMK Capital LLP, and other owners.

Since its foundation in 2005, BlueStep Bank has pioneered the specialist mortgage market in Sweden and Norway. By a differentiated approach to customer on-boarding and loan underwriting, focusing on the customer’s underlying loan servicing ability, BlueStep Bank has provided more than 29,000 customers with loans since inception, building a loan portfolio of SEK 13 billion. BlueStep Bank is headquartered in Stockholm, Sweden and has approximately 200 employees.

“We are very excited to become part of the EQT family”, says Öyvind Thomassen, CEO of BlueStep Bank. “EQT’s entrepreneurial approach, vast sector knowledge and digital capabilities will be of valuable support in our continued growth ambitions”.

Albert Gustafsson, Partner at EQT Partners, Investment Advisor to EQT VII, adds: “We are impressed by BlueStep Bank’s operations, track record and management team. The Company has created the specialist mortgage market in the Nordic region and has a market leading position today. We are convinced that EQT VII is the right partner to support the development of BlueStep Bank by focus and investment into further growth.”

Patrik Johnson, Partner at Bregal Capital LLP and EMK Capital LLP said: “BlueStep Bank is a responsible lender serving an important and growing niche. We are grateful to the management team for their significant achievement in building BlueStep Bank into what it is today and believe that they together with EQT have many exciting opportunities ahead of them”.

The transaction is subject to ownership approval from the Swedish Financial Supervisory Authority and from competition authorities, and is expected to close during fourth quarter of 2017. The parties have agreed not to disclose the transaction value.

Contacts:
Albert Gustafsson, Partner at EQT Partners, Investment Advisor to EQT VII +46 8 506 553 44
Öyvind Thomassen, CEO BlueStep Bank +46 8 501 005 04
EQT Press Office +46 8 506 553 34

About EQT
EQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtpartners.com

About BlueStep Bank
BlueStep Bank AB (publ) is a Swedish bank with presence in Sweden and Norway. The bank is specialized in catering for the growing share of the population that are not being served by traditional banks. BlueStep focuses on understanding each customers’ situation and their future financial capabilities. BlueStep offers both lending products and deposits. The company has been operating since 2005 and have approximately 200 employees. The Company has its headquarter in Stockholm, an office in Helsingborg and a branch office in Oslo, Norway. BlueStep Bank is licensed by the Swedish Financial Supervisory Authority.

More info: www.bluestepbank.com  

About EMK Capital
EMK Capital LLP is an independent private equity firm, established to continue the investment track record of Edmund Lazarus (previously Founder and Managing Partner of Bregal Capital) and Mark Joseph (previously Founder and Partner at Oakley Capital Private Equity) and to continue to manage portfolio companies of Bregal Capital. EMK is focused on investing in businesses with unrecognised and/or hard to realise value and where EMK can support management teams in executing transformative change. The firm closed its first fund in May 2017 at its hard cap of £575 million.

More info: www.emkcapital.com

About Bregal Investments
Bregal Investments is a global private equity firm which has over US $10 billion in invested or committed capital. The firm invests through several dedicated funds including: Bregal Freshstream, a UK and Benelux focused middle market private equity fund, Bregal Unternehmerkapital, Equity Capital for mid-sized companies in German-speaking Europe, Bregal Partners, a North American middle market private equity fund, Bregal Energy, an Energy-focused private equity fund, Bregal Sagemount, a U.S. private equity fund for growth companies, Bregal Private Equity Partners, a global investor in private equity funds and secondaries.

More info: www.bregal.com

 

Categories: News

Tags:

Ardian acquires ~ €300 million infrastructure private equity portfolio from UniCredit

New York, July 28, 2017 – Ardian, the independent private investment company, announces it has signed a Sale and Purchase Agreement in July 2017 with UniCredit for the acquisition of a ~ €300 million portfolio of limited partnership interests in European infrastructure private equity funds. Closing of the transaction is expected in 3Q17 subject to the approval and rules of the fund manager. This deal represents one of the largest secondary infrastructure transactions in 2017 and confirms Ardian’s leadership in secondary infrastructure Funds of Funds.

UniCredit is a simple successful Pan European Commercial Bank, with a fully plugged in CIB, delivering a unique Western, Central and Eastern European network to its extensive client franchise: 25 million clients. UniCredit offers local expertise as well as an international one reaching and supporting its clients globally, providing them with unparalleled access to leading banks in its 14 core markets as well as in other 18 countries worldwide.

This transaction continues Ardian’s secondary funds strategy to offer liquidity to large institutions looking to rebalance their portfolios and monetize their private equity investments. In 2016, the Ardian Fund of Funds team totaled $4.8 billion of secondary, infrastructure secondary and early secondary transactions worldwide.

“This is the culmination of a highly collaborative relationship with UniCredit,” said Mark Benedetti, Managing Director and Co-Head of Ardian US. “This acquisition highlights our unique ability to complete significant and complex transactions which offer secondary liquidity to large institutions such as Unicredit. Our scale and knowledge of the assets meant we were perfectly placed to support its strategy.”

“Our team, spread out across the globe, is able to access a vast amount of information via a database of 1,400 funds and 10,000 underlying companies, which gives us excellent perspective on pricing and quality, allowing us to be opportunistic on behalf of our investors,” said Mark Benedetti.

ABOUT ARDIAN

Ardian, founded in 1996 and led by Dominique Senequier, is an independent private investment company with assets of US$62 billion managed or advised in Europe, North America and Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian’s investment process embodies three values: excellence, loyalty and entrepreneurship.

Ardian maintains a truly global network, with more than 460 employees working through twelve offices in Beijing, Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, New York, Paris, San Francisco, Singapore and Zurich. The company offers its 580 investors a diversified choice of funds covering the full range of asset classes, including Ardian Funds of Funds (primary, early secondary and secondary), Ardian Private Debt, Ardian North America Direct Buyout, Direct Funds (Ardian Mid Cap Buyout, Ardian Expansion, Ardian Growth, Ardian Co-Investment), Ardian Infrastructure, Ardian Real Estate and customized mandate solutions with Ardian Mandates.

www.ardian.com

ABOUT UNICREDIT

UniCredit is a simple successful Pan European Commercial Bank, with a fully plugged in CIB, delivering a unique Western, Central and Eastern European network to its extensive client franchise: 25 million clients.

UniCredit offers local expertise as well as an international one reaching and supporting its clients globally, providing them with unparalleled access to leading banks in its 14 core markets as well as in other 18 countries worldwide. UniCredit European banking network includes Italy, Germany, Austria, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Romania, Russia, Serbia, Slovakia, Slovenia and Turkey.

PRESS CONTACTS

 

Categories: News

Tags:

Acino divests its patch business to Luye Pharma Group Ltd.

Nordic Capital Logo

Acino divests its patch business to Luye Pharma Group Ltd.

Today Acino International AG and Acino Pharma AG (together “Acino”) have signed a definitive agreement with Luye Pharma Group Ltd. (“Luye”) to sell Acino’s transdermal patch and implant businesses. The divestment includes Acino’s transdermal manufacturing operations, distribution, and R&D capabilities.

The divestment is in line with Acino’s strategy of shaping the organization for growth in emerging markets and further expanding Acino’s regional commercial presence in its key markets of the Middle East and Africa, the CIS region, and Latin America.

“The divestment will allow us to focus on growth in our key markets, and we believe that Luye’s vision and strategy will further the expansion of Acino’s existing R&D and manufacturing capabilities in Miesbach. An R&D focused company like Luye will be able to leverage the high potential of our transdermal business in the best possible way in the future, including further global expansion”, says Kalle Känd, CEO at Acino. After closing, Acino will retain the marketing rights to certain transdermal patches in its strategic emerging markets.

“As we execute our international strategy, this transaction serves as an important milestone. With its innovative technology platform, focused product portfolio, loyal customer base and experienced leadership, this acquisition will significantly enhance Luye’s international capabilities and accelerate its penetration into broader therapeutic areas and geographies” said Dr. Yehong Zhang, Luye Pharma (International) CEO.

Closing is expected to occur in the second half of 2016. Approximately 200 employees in Miesbach have been informed about the divestment to Luye during a Town Hall meeting.

About Acino

Acino, a Swiss pharmaceutical company headquartered in Zurich, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents.

As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand “Acino Switzerland”, Acino markets Swiss-quality medicines in emerging markets with a focus on the Middle East, Africa, Russia/CIS and Latin America. More information on www.acino-pharma.com

About Luye

Luye Pharma Group Ltd. (the “Company”, together with its subsidiaries collectively the “Group” or “Luye”) focuses on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fastest growing therapeutic areas – oncology, cardiovascular, metabolism and the central nervous system(“CNS”) therapeutic area. The Group has 30 product portfolio in the market and 21 product candidates in China and 7 product candidates overseas, among which five candidates have entered into the clinical trial stage in the United States of America (the “U.S.”) under U.S. Food and Drug Administration rules.

The Group has established production facilities and research and development (“R&D”) centers in China as well as offices in US, Malaysia and Singapore with over 3,400 employees, including over 300 R&D personnel. The Group’s products are marketed and sold in a vast majority of provinces, autonomous regions and municipalities in the PRC, as well as a number of foreign countries and regions. The Group’s nationwide sales and distribution network enabled it to sell its products to over 10,000 hospitals in the PRC.

On 9 July 2014, the shares of the Company were listed on the Main Board of the Stock Exchange of Hong Kong Limited. Over the past 22 years, the Group has grown into an international pharmaceutical group with market leading position in its key therapeutic areas. With the corporate value of “Professional Technology Serves Human Health” and the corporate philosophy of “Customer Orientation, Efficiency, and Employee Achievement”, the Group is committed to providing high quality pharmaceutical products and professional services for customers and patients.

Contact

Rory Fitzpatrick

Senior Communications Manager

Phone +41 44 555 22 90

Mobile +41 76 411 7138

rory.fitzpatrick@acino-pharma.com

 

 

Categories: News

Tags: